Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyra Therapeutics (LYRA) Other Non-Current Assets (2021 - 2025)

Historic Other Non-Current Assets for Lyra Therapeutics (LYRA) over the last 5 years, with Q3 2025 value amounting to $2.0 million.

  • Lyra Therapeutics' Other Non-Current Assets rose 5.02% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 million, marking a year-over-year increase of 5.02%. This contributed to the annual value of $2.0 million for FY2024, which is 4317.53% up from last year.
  • Latest data reveals that Lyra Therapeutics reported Other Non-Current Assets of $2.0 million as of Q3 2025, which was up 5.02% from $2.0 million recorded in Q2 2025.
  • In the past 5 years, Lyra Therapeutics' Other Non-Current Assets ranged from a high of $7.5 million in Q3 2023 and a low of $329000.0 during Q1 2021
  • Over the past 5 years, Lyra Therapeutics' median Other Non-Current Assets value was $2.0 million (recorded in 2024), while the average stood at $2.1 million.
  • Per our database at Business Quant, Lyra Therapeutics' Other Non-Current Assets skyrocketed by 44194.53% in 2022 and then crashed by 7330.83% in 2024.
  • Over the past 5 years, Lyra Therapeutics' Other Non-Current Assets (Quarter) stood at $762000.0 in 2021, then skyrocketed by 333.07% to $3.3 million in 2022, then tumbled by 57.82% to $1.4 million in 2023, then skyrocketed by 43.18% to $2.0 million in 2024, then changed by 0.0% to $2.0 million in 2025.
  • Its Other Non-Current Assets was $2.0 million in Q3 2025, compared to $2.0 million in Q2 2025 and $2.0 million in Q1 2025.